Covaxin gets emergency use nod for children aged 2-18 years
The Subject Expert Committee (SEC) of the drug regulator has recommended granting an emergency use authorisation to Covaxin for 2-18 age group. Bharat Biotech's Covaxin was granted restricted emergency use approval in 'clinical trial mode' on January 2. The Subject Expert Committee (SEC) of the drug regulator has recommended granting an emergency use authorisation to Bharat Biotech's Covaxin for children aged between 2-18. The SEC has submitted its recommendation to the Drugs Controller General of India (DCGI) for final approval. “After detailed deliberation, the committee recommended for grant of market authorization of the vaccine for the age group of 2 to 18 years for restricted use in an emergency situation," the expert panel said in a statement. It said that the emergency use authorisation, however, is subject to four conditions. "The developer of Covaxin will continue the study as per Whole Virion, Inactivated Corona Virus Vaccine the approved